Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Free Cash Flow (2020 - 2025)

RxSight's Free Cash Flow history spans 6 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 75.79% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$19.3 million, up 13.6%, while the annual FY2025 figure was -$19.3 million, 13.6% up from the prior year.
  • Free Cash Flow reached -$2.3 million in Q4 2025 per RXST's latest filing, down from -$1.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $486000.0 in Q3 2024 to a low of -$18.0 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$9.6 million, with a median of -$10.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 108.64% in 2024, then tumbled 463.79% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$10.5 million in 2021, then plummeted by 52.95% to -$16.1 million in 2022, then soared by 47.99% to -$8.4 million in 2023, then fell by 11.17% to -$9.3 million in 2024, then surged by 75.79% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Free Cash Flow are -$2.3 million (Q4 2025), -$1.8 million (Q3 2025), and -$6.3 million (Q2 2025).